These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30312409)

  • 1. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H
    J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients.
    Baklouti S; Massip C; Mane C; Guet-Revillet H; Murris M; Concordet D; Gandia P
    J Antimicrob Chemother; 2019 Oct; 74(10):3122-3123. PubMed ID: 31335940
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Mazer DM; Young C; Kalikin LM; Spilker T; LiPuma JJ
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS; Flamm RK; Carvalhaes CG; Castanheira M
    Diagn Microbiol Infect Dis; 2020 Mar; 96(3):114833. PubMed ID: 31924426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children.
    Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S
    Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
    Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
    Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Nolan PJ; Jain R; Cohen L; Finklea JD; Smith TT
    Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115204. PubMed ID: 33152675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.
    Becka SA; Zeiser ET; LiPuma JJ; Papp-Wallace KM
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0133221. PubMed ID: 34370574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.
    Gonzalez MD; McMullen AR; Wallace MA; Crotty MP; Ritchie DJ; Burnham CA
    Ann Lab Med; 2017 Mar; 37(2):174-176. PubMed ID: 28029009
    [No Abstract]   [Full Text] [Related]  

  • 14. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK; Clancy CJ; Pasculle AW; Press EG; Haidar G; Hao B; Chen L; Kreiswirth BN; Nguyen MH
    J Clin Microbiol; 2018 Feb; 56(2):. PubMed ID: 29167294
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Grohs P; Taieb G; Morand P; Kaibi I; Podglajen I; Lavollay M; Mainardi JL; Compain F
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New cephalosporins].
    Olarte-Luis T; Cáceres-Galíndez D; Cortés JA
    Rev Chilena Infectol; 2018; 35(5):465-475. PubMed ID: 30724992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.
    Mathy V; Grohs P; Compain F
    J Med Microbiol; 2018 Sep; 67(9):1217-1220. PubMed ID: 30016231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.